• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

两种用于卵巢癌风险术前评估的体外诊断多变量指数检测（IVDMIAs）的临床性能比较。

Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for Presurgical Assessment for Ovarian Cancer Risk.

机构信息

Division of Clinical Genetics, Department of Obstetrics and Gynecology, Feinberg School of Medicine of Northwestern University, Chicago, IL, USA.

Aspira Labs, Vermillion, Inc., Austin, TX, USA.

出版信息

Adv Ther. 2019 Sep;36(9):2402-2413. doi: 10.1007/s12325-019-01010-8. Epub 2019 Jul 5.

DOI:10.1007/s12325-019-01010-8
PMID:31278693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6822837/
Abstract

INTRODUCTION

Adnexal or pelvic mass is a finding that commonly raises suspicion for malignancy, especially for ovarian cancer. Proper identification prior to surgery would permit appropriate referral to a specialty center in cases likely to be ovarian cancer, as optimal outcomes in such cases are obtained when surgical staging and treatment are provided at the time of initial surgery.

METHODS

We compared the screening capabilities of two in vitro diagnostic multivariate index assays (IVDMIAs), a new IVDMIA (second-generation multivariate index assay: MIA2G) and a currently used triage algorithm (Risk of Ovarian Malignancy Assay: ROMA).

RESULTS

Among 245 subjects (24.7%) determined to have a malignancy, ROMA misclassified 51 malignancies (including 10 high-grade ovarian malignancies), whereas MIA2G misclassified 22 (including 5 high-grade ovarian malignancies). Early stage cancers were more frequently misclassified by ROMA (20 vs. 8 cases). The rate of "test-negative" malignancies was significantly higher for ROMA, while the rate of "test-positive" benign cases was significantly higher for MIA2G.

CONCLUSION

Triage algorithms play an important role in improving clinical outcomes for women presenting with an adnexal mass regardless of the eventual diagnosis. In this study, MIA2G was shown to correctly predict more cases of ovarian cancer than the ROMA algorithm.

FUNDING

Aspira Labs/Vermillion Inc.

摘要

简介

附件或盆腔肿块是一种常见的恶性肿瘤可疑表现，尤其是卵巢癌。在手术前进行正确的识别，将有助于将可能为卵巢癌的病例适当转诊至专业中心，因为在这种情况下，当在初次手术时提供手术分期和治疗时，才能获得最佳的结果。

方法

我们比较了两种体外诊断多变量指数检测（IVDMIAs）的筛查能力，一种是新的 IVDMIA（第二代多变量指数检测：MIA2G）和当前使用的分诊算法（卵巢恶性肿瘤风险检测：ROMA）。

结果

在 245 名（24.7%）被确定为恶性肿瘤的患者中，ROMA 错误分类了 51 例恶性肿瘤（包括 10 例高级别卵巢恶性肿瘤），而 MIA2G 错误分类了 22 例（包括 5 例高级别卵巢恶性肿瘤）。早期癌症更常被 ROMA 错误分类（20 例与 8 例）。ROMA 的“阴性测试”恶性肿瘤率明显更高，而 MIA2G 的“阳性测试”良性病例率明显更高。

结论

分诊算法在改善因附件肿块就诊的女性的临床结局方面发挥着重要作用，无论最终诊断如何。在这项研究中，与 ROMA 算法相比，MIA2G 被证明能够更正确地预测更多的卵巢癌病例。

资金来源

Aspira Labs/Vermillion Inc.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f3/6822837/e148dd78955b/12325_2019_1010_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f3/6822837/e148dd78955b/12325_2019_1010_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a0f3/6822837/e148dd78955b/12325_2019_1010_Fig1_HTML.jpg

相似文献

1
Clinical Performance Comparison of Two In-Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for Presurgical Assessment for Ovarian Cancer Risk.两种用于卵巢癌风险术前评估的体外诊断多变量指数检测（IVDMIAs）的临床性能比较。
Adv Ther. 2019 Sep;36(9):2402-2413. doi: 10.1007/s12325-019-01010-8. Epub 2019 Jul 5.
2
Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.附件包块良恶性风险第二代多变量指数检测方法的验证。
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11. doi: 10.1016/j.ajog.2016.03.003. Epub 2016 Mar 10.
3
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.评估 HE4、CA125、卵巢恶性肿瘤风险算法（ROMA）和恶性肿瘤指数（RMI）在盆腔肿块患者中作为上皮性卵巢癌的诊断工具。
Gynecol Oncol. 2012 Nov;127(2):379-83. doi: 10.1016/j.ygyno.2012.07.106. Epub 2012 Jul 24.
4
Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study.单独检测 CA125 与卵巢恶性肿瘤风险算法（ROMA）在附件包块患者中的比较：一项多中心研究。
Curr Probl Cancer. 2020 Apr;44(2):100508. doi: 10.1016/j.currproblcancer.2019.100508. Epub 2019 Nov 1.
5
Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.联合症状指数和第二代多变量生物标志物检测在附件包块患者中预测卵巢癌的应用。
Gynecol Oncol. 2018 Aug;150(2):318-323. doi: 10.1016/j.ygyno.2018.06.004. Epub 2018 Jun 19.
6
Comparison of the predictive performance of risk of malignancy indexes 1-4, HE4 and risk of malignancy algorithm in the triage of adnexal masses.比较风险恶性指数 1-4、HE4 和风险恶性算法在附件包块分诊中的预测性能。
J Ovarian Res. 2020 Apr 25;13(1):46. doi: 10.1186/s13048-020-00643-6.
7
Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?血清 HE4 或 ROMA 评分是否有助于有经验的检查者在经阴道超声检查后改善附件肿块的特征化？
Ultrasound Obstet Gynecol. 2014 Jan;43(1):89-97. doi: 10.1002/uog.12551. Epub 2013 Dec 4.
8
A comparison between an ultrasound based prediction model (LR2) and the risk of ovarian malignancy algorithm (ROMA) to assess the risk of malignancy in women with an adnexal mass.基于超声的预测模型（LR2）与卵巢恶性肿瘤风险算法（ROMA）在评估附件包块女性恶性肿瘤风险中的比较。
Gynecol Oncol. 2013 May;129(2):377-83. doi: 10.1016/j.ygyno.2013.01.018. Epub 2013 Jan 27.
9
Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass.两种多标志物血液检测对附件包块女性恶性肿瘤预测的临床性能
Clin Chim Acta. 2015 Jan 1;438:358-63. doi: 10.1016/j.cca.2014.09.028. Epub 2014 Oct 2.
10
Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.HE4、CA125 和 ROMA 算法在盆腔肿块女性中的比较：与病理结果的相关性。
Gynecol Oncol. 2013 Feb;128(2):233-8. doi: 10.1016/j.ygyno.2012.11.026. Epub 2012 Nov 28.

引用本文的文献

1
Tumour extracellular vesicle surface Protein-mRNA integration assay for early detection of epithelial ovarian cancer.用于上皮性卵巢癌早期检测的肿瘤细胞外囊泡表面蛋白质-信使核糖核酸整合检测法
EBioMedicine. 2025 Aug 12;119:105884. doi: 10.1016/j.ebiom.2025.105884.
2
Ovarian Cancer: Multi-Omics Data Integration.卵巢癌：多组学数据整合
Int J Mol Sci. 2025 Jun 21;26(13):5961. doi: 10.3390/ijms26135961.
3
Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.卵巢癌的诊断生物标志物：超越CA125和HE4的进展。

本文引用的文献

1
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).在 473 名连续的卵巢癌患者中发现有害的种系变异：观察性 AGO-TR1 研究的结果（NCT02222883）。
J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.
2
Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.联合症状指数和第二代多变量生物标志物检测在附件包块患者中预测卵巢癌的应用。
Gynecol Oncol. 2018 Aug;150(2):318-323. doi: 10.1016/j.ygyno.2018.06.004. Epub 2018 Jun 19.
3
Ther Adv Med Oncol. 2024 Feb 29;16:17588359241233225. doi: 10.1177/17588359241233225. eCollection 2024.
4
Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.个体化与精准纳米医学治疗卵巢癌。
Small. 2024 Oct;20(41):e2307462. doi: 10.1002/smll.202307462. Epub 2024 Feb 11.
5
HPLC for simultaneous quantification of free mannose and glucose concentrations in serum: use in detection of ovarian cancer.用于同时定量血清中游离甘露糖和葡萄糖浓度的高效液相色谱法：在卵巢癌检测中的应用
Front Chem. 2023 Nov 9;11:1289211. doi: 10.3389/fchem.2023.1289211. eCollection 2023.
6
Autoantibodies to Oxidatively Modified Peptide: Potential Clinical Application in Coronary Artery Disease.氧化修饰肽自身抗体：在冠状动脉疾病中的潜在临床应用
Diagnostics (Basel). 2022 Sep 20;12(10):2269. doi: 10.3390/diagnostics12102269.
7
Clinical Performance of a Multivariate Index Assay in Detecting Early-Stage Ovarian Cancer in Filipino Women.一种多变量指数检测在菲律宾女性早期卵巢癌检测中的临床性能。
Int J Environ Res Public Health. 2022 Aug 11;19(16):9896. doi: 10.3390/ijerph19169896.
8
Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.卵巢癌筛查与诊断的当前及新兴方法：全面综述
Cancers (Basel). 2022 Jun 11;14(12):2885. doi: 10.3390/cancers14122885.
9
Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.蛋白质组学在卵巢癌中的应用：新时代的曙光。
Proteomes. 2022 May 9;10(2):16. doi: 10.3390/proteomes10020016.
10
Biomarkers and Strategies for Early Detection of Ovarian Cancer.卵巢癌的早期检测的生物标志物和策略。
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2504-2512. doi: 10.1158/1055-9965.EPI-20-1057. Epub 2020 Oct 13.
Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
不同策略对附件包块女性分诊的诊断准确性和成本效益：一项前瞻性研究。
Ultrasound Obstet Gynecol. 2017 Sep;50(3):395-403. doi: 10.1002/uog.17320.
4
Refining Ovarian Cancer Test accuracy Scores (ROCkeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer.优化卵巢癌检测准确性评分（ROCkeTS）：一项前瞻性纵向检测准确性研究的方案，用于验证疑似卵巢癌症状女性的新风险评分。
BMJ Open. 2016 Aug 9;6(8):e010333. doi: 10.1136/bmjopen-2015-010333.
5
Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses.附件包块良恶性风险第二代多变量指数检测方法的验证。
Am J Obstet Gynecol. 2016 Jul;215(1):82.e1-82.e11. doi: 10.1016/j.ajog.2016.03.003. Epub 2016 Mar 10.
6
Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors.多元指标检测在卵巢肿瘤术前评估中的应用效果。
Obstet Gynecol. 2011 Jun;117(6):1289-1297. doi: 10.1097/AOG.0b013e31821b5118.
7
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.一种利用人附睾蛋白4（HE4）和癌抗原125（CA125）预测盆腔肿块患者卵巢癌的新型多标志物生物测定法。
Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12.
8
Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.通过专业超声检查与血清CA-125鉴别附件良恶性肿块
J Natl Cancer Inst. 2007 Nov 21;99(22):1706-14. doi: 10.1093/jnci/djm199. Epub 2007 Nov 13.
9
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals.在教学医院接受手术的晚期卵巢癌、输卵管癌和腹膜癌患者的短期生存率有所提高。
Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:11-7. doi: 10.1111/j.1525-1438.2006.00319.x.
10
Management of the adnexal mass.附件肿物的管理
Gynecol Oncol. 1994 Dec;55(3 Pt 2):S42-6. doi: 10.1006/gyno.1994.1340.